Jubilant Ingrevia Limited, in its Board Meeting held on May 26, 2026, approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026. The company reported its financial performance, showing a comparative analysis of its revenue and profit against the previous quarter and the corresponding quarter of the previous year. Jubilant Ingrevia Limited is a global integrated Life Science products and innovative solutions provider, serving pharmaceutical, nutrition, agrochemical, consumer, and industrial customers.

Note: The percentage changes are based on the latest available market data provided for the recent financial results.

Jubilant Ingrevia Limited is a major global player in Life Science Ingredients and Specialty Chemicals, with a legacy spanning over 40 years. The company specializes in products such as Pyridine, Picolines, Vitamin B3, and Acetic Anhydride. As of 2025, the company has focused on navigating chemical industry headwinds, including pricing pressures and energy costs, through volume growth in its Agrochemical and Nutrition & Health Solutions segments. Recent updates include the commissioning of a new boiler at their Bharuch site and the commencement of construction on a new multipurpose plant in Gajraula to bolster CDMO capacity. The company has a notable institutional presence, with major investors including DSP Small Cap Fund and various trusts associated with the promoter family.